Praxis Precision Medicines Inc   (PRAX)
Other Ticker:  
Price: $47.5100 $5.87 14.097%
Day's High: $48.38 Week Perf: 18.18 %
Day's Low: $ 40.58 30 Day Perf: 28.47 %
Volume (M): 223 52 Wk High: $ 50.55
Volume (M$): $ 10,576 52 Wk Avg: $20.85
Open: $41.41 52 Wk Low: $11.85

 Market Capitalization (Millions $) 429
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -138
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 0

Praxis Precision Medicines Inc
Praxis Precision Medicines Inc is a biopharmaceutical company focused on discovering and developing targeted therapies for patients suffering from central nervous system disorders. The company leverages its expertise in neuroscience and genetic research to identify novel drug targets and develop precision medicines that address the underlying causes of these disorders. Praxis aims to provide patients with personalized treatments that can improve their quality of life.

   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 300-8460   Stock Exchange / Ticker: NASDAQ PRAX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): A Promising Future for Precision Medicine

Published Fri, Feb 2 2024 9:00 PM UTC

Praxis Precision Medicines, Inc. made an exciting announcement regarding inducement grants under Nasdaq Listing Rule 5635(c)(4). This move comes at a time when the company's share price is soaring, indicating its positive market performance. As of the writing of this article, Praxis Precision Medicines Inc's share price stands at $43.73, reflecting a remarkable inc...


Praxis Precision Medicines Announces Successful Pricing of $150 Million Public Offering

Published Thu, Jan 11 2024 12:30 PM UTC

Leading biopharmaceutical company, Praxis Precision Medicines, Inc. (NASDAQ: PRAX), has recently made a significant breakthrough by successfully pricing its underwritten public offering at $150.0 million. The offering, which consists of shares of common stock and pre-funded warrants, highlights Praxis' commitment to translating genetic insights into developing ther...


Praxis Precision Medicines Proposes Public Offering, Aiming to Expand Therapeutic Development for CNS Disorders

Published Wed, Jan 10 2024 9:19 PM UTC

BOSTON, Jan. 10, 2024 - Praxis Precision Medicines, a leading clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, has recently announced its plans for a proposed public offering of its common stock. The company aims to utilize the proceeds from the offering to further advance their innovative genetic-based...

Clinical Study

Praxis Precision Medicines Surpasses Expectations in Promising Study for Precision Epilepsy Treatment

Published Mon, Jan 8 2024 1:01 PM UTC

Praxis Precision Medicines, a leading biopharmaceutical company focused on developing precision therapies for central nervous system disorders, recently released an update on the progress of its clinical stage portfolio. In particular, the company reported positive preliminary analysis from the 15 mg cohort in the PRAX-628 study involving epilepsy patients with Photo-Paroxys...

Licensing Agreement

Praxis Precision Medicines and Tenacia Biotechnology Collaborate to Address Unmet Patient Needs in Greater China

Published Fri, Jan 5 2024 1:00 PM UTC

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China: Collaboration leverages Tenacia's expertise in central nervous system drug development and commercialization and will address a significant unmet patient needIn an exciting development for the field of precision medicines, Praxis Precisio...


Praxis Precision Medicines Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com